Table 2.

Incidence, severity, and etiology of AKI events

DescriptionAll Patients, n=1448Monotherapy, n=724Combination Therapy, n=724P Value
Person-months of treatment exposure37,44318,67818,765
Individuals with AKI210 (8.6)80 (11.0)130 (18.0)<0.001
AKI events295105190
No. of episodes (%) of AKI per individual0.30
 1a159 (75.7)63 (78.8)96 (73.8)
 2a31 (14.8)12 (15.0)19 (14.6)
 >2a20 (9.5)5 (6.2)15 (11.5)
AKI events per 100 person-yr (95% confidence interval)9.5 (8.4 to 10.6)6.7 (5.6 to 8.2)12.2 (10.5 to 14.0)<0.001
Severity of AKI0.71
No. of events (%) with evaluable data287 (97.3)103 (98.1)184 (96.8)
 >50%–100% increase in serum creatinineb109 (38.0)35 (34.0)74 (40.2)
 >100%–200% increase in serum creatinineb89 (31.0)37 (35.9)52 (28.3)
 >200% increase in serum creatinineb36 (12.5)10 (9.7)26 (14.1)
AKI events requiring RRTa (%)29 (10.1)12 (11.5)17 (9.1)0.49
Community- versus hospital-acquired AKI (%)0.79
 No. of events with evaluable data289 (98.0)104 (99.0)185 (97.4)
 Community acquiredb189 (65.4)67 (64.4)122 (65.9)
 Hospital acquiredb100 (34.6)37 (35.6)63 (34.1)
Etiology of episodes of AKIc (%)
 No. of events with evaluable data290 (98.3)104 (99.0)186 (97.9)
 Prerenalb218 (75.2)76 (73.1)142 (76.3)0.54
 Acute tubular necrosisb71 (24.5)25 (24.0)46 (24.7)0.90
 Acute interstitial nephritisb13 (4.5)7 (6.8)6 (3.2)0.17
 Obstructive uropathyb18 (6.2)8 (7.7)10 (5.4)0.43
 Otherb19 (6.6)8 (7.7)11 (5.9)0.56
  • a Percentages calculated on the basis of total number of AKI events.

  • b Percentages calculated on the basis of number of AKI events with evaluable data.

  • c Totals exceed 100%, because some patients were classified as having multifactorial AKI.